Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abivax SA - American Depositary Shares (NQ:ABVX)

130.82 +1.09 (+0.84%)
Streaming Delayed Price Updated: 2:53 PM EDT, May 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abivax SA - American Depositary Shares

< Previous 1 2 3 4 5 Next >
News headline image
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
From Abivax
Via GlobeNewswire
News headline image
2 Stocks That Could Realistically Double by 2030 ↗
Long-time shareholders are already pretty satisfied with these companies, but there might be even more upside ahead. 
Via The Motley Fool
News headline image
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases. 
Via The Motley Fool
News headline image
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗
Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions. 
Via The Motley Fool
News headline image
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish ↗
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗
Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases. 
Via The Motley Fool
News headline image
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗
Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗
Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗
This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Abivax Announces Results of its May 11, 2026 Annual General Meeting
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
From Abivax
Via GlobeNewswire
News headline image
Abivax to Present Data on Obefazimod at Digestive Disease Week®
From Abivax
Via GlobeNewswire
News headline image
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
From Abivax
Via GlobeNewswire
News headline image
This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy? ↗
We'll soon know more about the drugmaker's long-term prospects. 
Via The Motley Fool
News headline image
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
From Abivax
Via GlobeNewswire
News headline image
2 Healthcare Stocks That Could Soar Over the Next 5 Years ↗
They could make important breakthroughs in their target markets. 
Via The Motley Fool
News headline image
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
From Abivax
Via GlobeNewswire
News headline image
Goldman Sachs Bullish Forecast: 15% Increase in 2026 U.S. M&A Activity
As the first quarter of 2026 comes to a close, the financial world is buzzing with a renewed sense of optimism. Goldman Sachs (NYSE: GS) has released its highly anticipated 2026 Global M&A Outlook,... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
2 Healthcare Stocks to Buy Before They Get Bought Out ↗
Abivax and Nektar Therapeutics are clinical-stage biotech companies that would make attractive buyout targets. 
Via The Motley Fool
News headline image
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗
Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology. 
Via The Motley Fool
News headline image
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗
This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases. 
Via The Motley Fool
News headline image
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗
This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗
Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗
Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.